Understand the source comparison
Peptides for Achilles Recovery Protocol Evidence Guide: Full Comparison
Before choosing a protocol, understand how these peptides differ in mechanism, dosing, and application. | Peptide | Primary Mechanism | Dosing Protocol | Administration Route | Evidence Strength | Typical Recovery Timeline | Bottom Line Assessment ||—|—|—|—|—|
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before choosing a protocol, understand how these peptides differ in mechanism, dosing, and application.
- | Peptide | Primary Mechanism | Dosing Protocol | Administration Route | Evidence Strength | Typical Recovery Timeline | Bottom Line Assessment ||—|—|—|—|—|—|| BPC-157 | VEGF/bFGF upregulation, neovascularization, collagen synthesis | 250–500 mcg twice daily, 4–6 weeks | Subcutaneous near injury site or IM in gastrocnemius | Moderate (Phase I/II human trials, robust animal models) | 6–8 weeks to pain-free loading | Best for localized tendon injuries requiring rapid collagen deposition. Stack with TB-500 for synergistic effect || TB-500 | Actin regulation, fibroblast migration, inflammation modulation | Loading: 2–2.5 mg twice weekly for 4 weeks; Maintenance: 2–2.5 mg weekly | Subcutaneous or IM (systemic) | Moderate (animal models, equine trials, limited human data) | 7–9 weeks to functional strength | Best for reducing fibrosis and maintaining elasticity. Longer half-life allows less frequent dosing || GHK-Cu (Copper Peptide) | Collagen stimulation, antioxidant, MMP regulation | 1–2 m